Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is expected to see continued growth in 2026 due to the release of their Q2 financial and operational results, including a Preliminary Economic Assessment with a positive after-tax NPV5% and IRR. Additionally, the recent repurchase of shares and quarter dividend payment show the company's commitment to returning capital to shareholders, which further strengthens its financial position. With its strong product offerings and expansion into new markets, 10x Genomics is well-positioned for continued success in the years to come.

Bears say

10x Genomics is facing significant risks to achieving its projected target due to increasing competition in the life science technology industry, the potential for its technology to become obsolete, and potential disruptions in its supply chain. These risks, along with the company's dependence on key customers and potential regulatory challenges, warrant a negative outlook on the stock. Relevant financial data that may support this outlook includes the fact that the company has a P/E ratio of 338.72, indicating a high valuation that may not be justified by its financial performance.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.